Please try another search
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Name | Age | Since | Title |
---|---|---|---|
Martin W. MacKay | 67 | 2018 | Co-Founder & Executive Chairman |
Lucian Iancovici | 40 | 2020 | Independent Director |
Stephen Uden | 65 | 2018 | Co-Founder, President, CEO & Director |
Ronald M. Hunt | 58 | 2019 | Independent Director |
Paula Soteropoulos | 55 | 2020 | Independent Director |
Robert L. Hopfner | 50 | 2020 | Independent Director |
Christine A. Nash | 50 | 2022 | Independent Director |
Kush M. Parmar | 43 | 2018 | Independent Director |
Hui Liu | 56 | 2022 | Independent Director |
Helen Marie Boudreau | 57 | 2020 | Independent Director |
Wendy K. Chung | 53 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review